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Role of peripheral blood minimum 
residual disease at day 8 of 
induction therapy in high-risk 
pediatric patients with acute 
lymphocytic leukemia
Thais Ditolvo da Costa Salina1,2, Yvelise Antunes Ferreira1, Eliana Brasil Alves1,2, 
Cristina Motta Ferreira1, Erich Vinícius De Paula1,3, Marcelo Távora Mira1,4 & 
Leny da Mota Passos1
Risk stratification and treatment intensification, based on minimal residual disease (MRD) 
mensurement, changed the prognosis of pediatric patients with acute lymphocytic leukemia (ALL). 
The main aim of this study was to investigate whether peripheral blood (PB) MRD measurement at day 
8 (D8) could predict the risk stratification category determined by bone marrow (BM) MRD at day 15 
(D15). The study was performed prospectively, in a cohort of 40 children with B-lineage ALL, adopting 
the protocol of the Brazilian Cooperative Group of the Treatment Childhood Leukemia (GBTLI-2009). 
MRD was detected by flow cytometry (FC) using a simplifed panel that can reliably identify MRD at early 
phases of induction therapy. Upon diagnosis, the proportion of low and high-risk patients, was 24:16 
(60%:40%). The main result of our study demonstrated the potential of D8 MRD in anticipating of week 
the risk stratification of high-risk patients as determined by D15 BM MRD. In these patients D8 MRD 
level of 1% was able to segregate high risk fast responders from high risk slow responders (p = 0.0097). 
This result could represent an opportunity for early treatment intensification, as already performed in 
some protocols.
The recent increase in survival rates observed in acute lymphocytic leukemia (ALL) is due to advances in diag-
nosis, identification of critical prognostic factors and definition of treatment according to risk groups1–3. At 
diagnosis, the most important parameters for risk stratification, with minor differences across different therapy 
protocols, are age, white blood cell count, immunophenotype, presence of lymphoblasts in the central nervous 
system and molecular analysis of chromosomal abnormalities4,5. In addition, early response to induction chemo-
therapy is also a critical prognostic factor.
Historically, therapeutic response was assessed mostly by morphological count of blasts in peripheral blood 
(PB) and bone marrow (BM). However, due to the fact that patients in morphologic remission may present mor-
phologically undetectable amounts of residual leukemic cells, referred as “Minimal Residual Disease” (MRD), 
different strategies using flow cytometric or molecular techniques have been used to detect these cells in the last 
decades5–7. MRD measurement is actually superior to other traditional markers of disease and based in its result, 
is possible to optimize chemotherapy, minimizing toxicity and decreasing risk of relapse3–5,8,9.
Current ALL protocols associate morphological analysis with MRD measurement to evaluate treatment 
response on both early and late time-points, providing more timely and accurate prognostic information of 
treatment outcome2,4,10. However, on day 8 (D8), the earliest time point of assessment of therapeutic response, 
most protocols use morphological analysis of PB for risk stratification, with good and poor responses defined as 
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PB leukemic blast counts below and above 1,000/mm3, respectively11. In order to refine this D8 evaluation, the 
Children’s Oncology Group (COG) protocol adopted MRD analysis to guide treatment in this earliest time point, 
with positive outcomes on treatment response1. However, MRD evaluation at D8 has not been widely adopted, 
and several protocols still rely on morphological analysis. Here, we present the results of an independent study to 
evaluate the impact of D8 MRD measurement on risk stratification in a prospective cohort of 40 patients with ALL.
Patients and Methods
Study design and definitions. From January 2014 to January 2015, all children newly diagnosed with 
B-lineage ALL and admitted for treatment at our institution, which is the only institution that provides care for 
children with leukemia in the State of Amazonas in northern Brazil, were recruited for this study. T-lineage ALL 
and AML were excluded by immunophenotypical criteria based in a broad panel of monoclonal antibodies at 
diagnosis. The characterization of genetic abnormalities in bone marrow samples was performed by conventional 
cytogenetics at diagnosis. As per protocol definitions, alterations indicating the presence t(9;22) which is associ-
ated with BCR-ABL1, or t(4;11), which is associated with MLL rearranged were defined as high risk cytogenetic 
abnormalities.
After admission, parents/legal guardians were invited to participate and provided written informed con-
sent. The study was approved by the Committee of Ethics in Research of the Hematology and Hemotherapy 
Foundation of Amazonas (HEMOAM) and performed in accordance with the Declaration of Helsinki. Diagnosis 
was based on morphological and immunophenotypical criteria and patients were treated according to the guide-
lines of the Brazilian Cooperative Group for the Treatment of Childhood Leukemia (GBTLI-2009) (supplemen-
tary Figures 1 and 2). Patients were initially stratified as low or high risk at diagnosis according to clinical and 
laboratory criteria shown in Table 1.
Then, during induction, patients were restratified according to response to chemotherapy. As shown in Fig. 1, 
low risk patients at diagnosis were restratified as true low risk, intermediate low risk or high risk slow responders. 
On the other hand, high risk patients at diagnosis were restratified as high risk fast responders or high risk slow 
responders.
Laboratory analysis and interpretation. During induction, PB samples were obtained at D8 and BM samples 
at day 15 (D15) to measure MRD by flow cytometry (FC) according to previously published criteria2,3,10. Briefly, 
MRD measurement was performed using 4-colour flow cytometry analyzer (FacsCalibur, Becton Dickinson, 
Risk parameter Low risk (LR) High risk (HR)
Age, years ≥ 1 and < 9 < 1 or ≥ 9
White blood cell count < 50,000/mm3 ≥ 50,000/mm3
Lymphoblasts in the 
central nervous system Absent Present
Cytogenetics Absence of high-risk cytogenetic findings
Presence of high-risk 
cytogenetic findings 
t(9;22) BCR/ABL or 
t(4;11) MLL/AF4
Table 1.  Risk stratification criteria at diagnosis, according GBTLI 2009*. * Brazilian Cooperative Group for 
the Treatment of Childhood Leukemia12; the presence of any high risk criteria is sufficient to classify patients in 
this category, while, the absence of all high-risk parameters is required to incorporate in low risk strata.
Figure 1. Restratification during induction. Risk restratification criteria at days 8 and 15 of induction therapy, 
according to Brazilian Cooperative Group for the Treatment of Childhood Leukemia 2009 (GBTLI 2009).
www.nature.com/scientificreports/
3Scientific RepoRts | 6:31179 | DOI: 10.1038/srep31179
San Jose, CA, USA) using simplified FC panel of monoclonal antibodies that can be used into non-regenerative 
phases of treatment3 (Table 2). This simplified flow cytometric assay is based on expression of CD19, CD10, 
and CD34 antigens, that can reliably identify MRD at early phases of remission induction therapy. According 
to Coustan-Smith et al., normal lymphoid progenitors (CD19, CD10, and/or CD34) are exquisitely sensitive to 
corticosteroids and other antileukemic drugs. Therefore, cells with this phenotype detected early in treatment of 
patients with B-lineage ALL should be leukemic rather than normal cell3.
The number of residual leukemic cells was calculated as the percentage of blasts present within the total of 
nucleated cells counted. After gating on CD19 cells with lymphoid morphology (as defined by their forward and 
side light-scattering properties), we determined the percentages of CD19 cells expressing CD10 and/or CD34. 
Sensitivity, determined upon dilutions of leukemic blasts in normal BM or PB, was 0,01%. Morphology was ana-
lyzed at the same time points by an investigator blinded to MRD results.
Based on BM MRD at D15, patients were assigned to different risk stratification groups, according to GBTLI-
2009 criteria, presented above12. Next, the association between PB MRD at D8 and risk stratification at D15 was 
examined.
Statistical analysis. Descriptive statistics were used to report demographical and clinical data. Data 
are expressed as median, ranges, means and SD. Differences in continuous variables were analyzed using the 
Mann-Whitney test. Categorical variables were compared using the Fisher’s exact test. A p value less than or equal 
to 0.05 was considered statistically significant. All statistical analyses were performed using the GraphPad Prism 
Software (GraphPad Prism Software Inc. San Diego, California, USA).
Results
Our study population, which represents all children treated for ALL during the study period in the State of 
Amazonas, Brazil, consisted of 40 patients (23 males; 17 females) with a median age of 3.5 years (range 1–17). 
Additional social-demographic, clinical and laboratorial characteristics of the patients are shown in Tables 3 and 4.
Upon diagnosis, the proportion of low and high-risk patients, based on GBTL-2009 criteria was 24:16 
(60%:40%). A flowchart of enrolled patients is shown in Fig. 2. At D8, PB MRD data was available for 35 out of 
40 patients, with the five remaining patients evaluated only by morphology at this time-point. Although at D8 
manual blast count all patients presented less than 1,000 blasts/mm3, PB MRD levels revealed a more heteroge-
nous response in terms of MRD levels, with 68,5% of the patients presenting MRD between 0,01% and 10%; 20% 
presenting MRD ≥ 10%, and only 11,4% pesenting negative (MRD ≤ 0,01%) (Fig. 2).
Finally, we assessed whether PB MRD measurement at D8 could predict the risk stratification category deter-
mined by BM MRD at D15, thereby anticipating this important information (Fig. 3). In Fig. 3A, PB MRD at D8 
from low-risk patients (at diagnosis) is compared between the three risk stratification groups, as determined by 
levels of BM MRD at D15 (as previously detailed). Similar PB MRD levels at D8 were observed between patients 
from intermediate low risk and high risk. In contrast, the two patients assigned to the “true low risk” category by 
BM MRD at D15 were negative for PB MRD at D8 (Fig. 3A). Unfortunately, the low number of patients in this 
category precluded a formal statistical analysis. In Fig. 3B, PB MRD at D8 from high-risk patients (at diagnosis) 
is compared to fast and slow responders, according to D15 MRD (Fig. 1). Interestingly, a statistically significant 
difference of PB MRD levels could be detected at D8 (P = 0.0097). Of note, all high risk slow responders presented 
MRD level below 1% at D8.
Test-tube FITC PE PerCP APC
1 CD45 (20 uL) CD10 (15 uL) CD34 (15 uL) CD19 (4 uL)
2 CD45 (20 uL) IgG-1 (15 uL) CD34 (15 uL) CD19 (4 uL)
3 Syto-13® * — — CD19 (4 uL)
Table 2. Panel of monoclonal antibodies to identify minimal residual disease. * SYTO® 13 Green 
Fluorescent Nucleic Acid Stain: molecular probe from Invitrogen used to assess cell viability. All antibodies were 
purchased from Biotech, Exbio.
Variables (n = 40) n %
Gender
 Female 17 42.5
 Male 23 57.5
Age (median = 3,5 years)
 < 9 years old 30 75.0
 ≥ 9 years old 10 25.0
Ethnicity
 Caucasian 17 42.5
 Non-caucasian 23 57.5
Table 3. Social-demographic data of the study population. n = simple absolute frequency.
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Discussion
Risk stratification and selected treatment intensification based on MRD detection have changed the prognosis of 
ALL patients11. However, at D8, most protocols still use morphological criteria to evaluate treatment response, 
leaving more sensitive techniques for later time-points. However, the feasibility and potential benefits of using 
MRD measurement as early as D8 have been demonstrated by the COG group in 2008. This group demon-
strated that patients who had high levels of D8 PB MRD (> 1%) had a poor outcome even if they cleared their 
BM of MRD by the end of induction, especially in high risk patients1. Here, we aimed to evaluate whether the 
anticipation of MRD measurement from D15 to D8, using PB samples, could add relevant information to the 
management of patients with ALL, and thereby validate the COG findings in an independent cohort treated with 
a different protocol.
Our study was performed prospectively, in a population of consecutive patients, from a single center responsible 
for the treatment of all patients with ALL in the State of Amazonas, Brazil, an area with approximately 4 million inhab-
itants. The study was conducted in a relatively short time span, and all patients adopted the same treatment guidelines. 
The main result of our study was the demonstration that D8 MRD measured in PB samples could anticipate in one 
Variables (n = 40) n %
Hepatomegaly 22 55.0
Esplenomegaly 20 50.0
Adenomegaly 17 42.5
Leucocyte count at diagnosis
 < 50,000/mm3 32 80.0
 ≥ 50,000/mm3 8 20.0
Lymphoblasts in the central nervous system
 Positive 2 5.0
 Negative 38 95.0
Immunophenotype
 ALL B Calla positive 40 100.0
Cytogenetics
Metaphase absent 16 40.0
Metaphase present 24 60.0
 Hyperploidia 5/24 20.8
 t(9;22) 2/24 8.4
 Normal 17/24 70.8
Table 4. Clinical and laboratory characteristics of the study population. n = simple absolute frequency.
Figure 2. Comparison of manual blast count and MRD levels at day 8. Flowchart of the comparative analysis 
between manual blast count and PB MRD detected by flow cytometry (MRD-FC) at day 8.
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week the risk stratification of high-risk patients with ALL that was later determined by BM MRD, at D15. This result 
could represent an opportunity for early treatment intensification, as already performed in some protocols.
The potential of D8 MRD measurement to refine risk stratification during early phases of ALL treatment was 
clearly evident for patients that were classified as high-risk according to GBTLI criteria at diagnosis. In these 
patients D8 MRD level of 1% was able to segregate high risk fast from slow responders as early as at D8 in our 
population. A similar finding was described in a study of childhood ALL in the UK, which identifed the same 
MRD-FC level at D8 to segregate high risk from low risk pacients13.
In our low-risk patients this finding could not be confirmed, maybe due to the limited number of patients 
in this group. However, the fact that none of the patients from the “true low-risk” group presented PB MRD at 
D8 suggests that this strategy could also be informative in this group, which should be confirmed in additional 
studies.
Our study highlights the potential of D8 MRD measured in PB samples for anticipating in one week the risk 
stratification of high-risk patients with ALL, as determined by BM MRD at D15. This result could represent an 
opportunity for early treatment intensification, as already performed in some protocols. However, due to the 
short follow-up and relatively limited number of patients we are not able to test the impact of these results in 
clinically-relevant outcomes such as event-free and overall survival. We are following this population currently 
and increasing the cohort to obtain this data. Validation in a larger cohort of patients is still required. Based on 
future results, it will be possible to evaluate if treatment intensification, based on D8 MRD, should be incorpo-
rated to the Brazilian protocol schedule.
“Furthermore, another limitation of our study is the limited genetic characterization of our population, which 
was based only on conventional cytogenetics. It has been shown that the identification of additional submicro-
scopic genetic alterations, and the use of more sensitive techniques could further improve the stratification of 
childhood ALL, an issue that is still under investigation in prospective studies14. However, several recent stud-
ies about childhood ALL still rely only on clinical, hematological and cytogenetic parameters for risk stratifica-
tion15–18. In addition, limitations in the access to molecular biology techniques in some areas of Brazil (which is 
likely to be the case of a large proportion of treatment centers around the globe), also preclude the immediate 
adoption of some diagnostic tools in ongoing protocols. Therefore, while we acknowledge that it is not possible to 
rule out that the incorporation of more sensitive genetic markers could have changed our results, we believe that 
the well-established power of cytogenetics to define prognosis in childhood ALL19–22, and its widespread use in 
several recent reported clinical trials, makes this possibility less likely.
In conclusion, our results validate, in an independent population using a different protocol, that MRD meas-
urement at D8 of induction therapy in children with ALL can anticipate the information obtained by MRD only 
at D15 for high-risk patients.
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